Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· November 29, 2025

Marjorie Taylor Greene’s stocks jumped 476% since joining Congress: Here are her 5 biggest investing wins to learn from

View original at finance.yahoo.com
Marjorie Taylor Greene’s stocks jumped 476% since joining Congress: Here are her 5 biggest investing wins to learn from Marjorie Taylor Greene is leaving Congress, but not before one of the best investment runs ever by a sitting politician…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Criticism of her tariff trades is laughable because Trump has talked about tariffs for decades

    80% confidence

  • She learned about Palantir trades from media coverage

    80% confidence

  • Portfolio manager handles all trades under fiduciary agreement

    80% confidence

  • Greene's trades are another reason why stock trading by members of Congress or spouses should be banned

    80% confidence

  • She refuses to hide stock trades in blind trust and reports everything with full transparency

    80% confidence

  • She made all her net worth before becoming Member of Congress

    80% confidence

  • Greene resigned due to bitter falling out with Trump over demands to release Jeffrey Epstein files

    80% confidence

  • Greene is exhibit A for congressional corruption

    80% confidence

  • She doesn't sit on specific subcommittee that oversees ICE

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com